Tumor Lysis Syndrome Clinical Trial
Official title:
A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01724528 -
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00186940 -
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
|
N/A | |
| Completed |
NCT00230217 -
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
|
Phase 4 | |
| Completed |
NCT00360438 -
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
|
Phase 1/Phase 2 | |
| Completed |
NCT00628628 -
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
|
Phase 2 | |
| Terminated |
NCT03605212 -
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
|
Phase 1/Phase 2 | |
| Terminated |
NCT01097369 -
Elitek (Rasburicase) Immuno-Monitoring Study
|
N/A | |
| Recruiting |
NCT04745910 -
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
|
Phase 4 | |
| Completed |
NCT00230178 -
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
|
Phase 3 |